Thursday, July 31, 2014

The Trade: Valeant’s Cost-Cutting Ethos May Yet Give Wall Street Indigestion

Valeant Pharmaceuticals’ lean business model risks harming its relationship with the Food and Drug Administration and hampering its competitiveness.








via NYT > Business Day http://ift.tt/1ldELTV








via WordPress http://ift.tt/1AElOn6
Posted by at
Labels: , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)